Predicting In Vivo Anti-Hepatofibrotic Drug Efficacy Based on In Vitro High-Content Analysis

Background/Aims Many anti-fibrotic drugs with high in vitro efficacies fail to produce significant effects in vivo. The aim of this work is to use a statistical approach to design a numerical predictor that correlates better with in vivo outcomes. Methods High-content analysis (HCA) was performed with 49 drugs on hepatic stellate cells (HSCs) LX-2 stained with 10 fibrotic markers. ~0.3 billion feature values from all cells in >150,000 images were quantified to reflect the drug effects. A systematic literature search on the in vivo effects of all 49 drugs on hepatofibrotic rats yields 28 papers with histological scores. The in vivo and in vitro datasets were used to compute a single efficacy predictor (Epredict). Results We used in vivo data from one context (CCl4 rats with drug treatments) to optimize the computation of Epredict. This optimized relationship was independently validated using in vivo data from two different contexts (treatment of DMN rats and prevention of CCl4 induction). A linear in vitro-in vivo correlation was consistently observed in all the three contexts. We used Epredict values to cluster drugs according to efficacy; and found that high-efficacy drugs tended to target proliferation, apoptosis and contractility of HSCs. Conclusions The Epredict statistic, based on a prioritized combination of in vitro features, provides a better correlation between in vitro and in vivo drug response than any of the traditional in vitro markers considered.Institute of Bioengineering and Nanotechnology (Singapore)Singapore. Biomedical Research CouncilSingapore. Agency for Science, Technology and ResearchSingapore-MIT Alliance for Research and Technology Center (C-185-000-033-531)Janssen Cilag (R-185-000-182-592)Singapore-MIT Alliance Computational and Systems Biology Flagship Project (C-382-641-001-091)Mechanobiology Institute, Singapore (R-714-001-003-271

siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells

<p>Abstract</p> <p>Background</p> <p>Doxorubicin is an effective breast cancer drug but is hampered by a severe, dose-dependent toxicity. Concomitant administration of doxorubicin and another cancer drug may be able to sensitize tumor cells to the cytotoxicity of doxorubicin and lowers the therapeutic dosage. In this study, we examined the combined effect of low-dose doxorubicin and siRNA inhibition of telomerase on breast cancer cells. We found that when used individually, both treatments were rapid and potent apoptosis inducers; and when the two treatments were combined, we observed an enhanced and sustained apoptosis induction in breast cancer cells.</p> <p>Methods</p> <p>siRNA targeting the mRNA of the protein component of telomerase, the telomerase reverse transcriptase (hTERT), was transfected into two breast cancer cell lines. The siRNA inhibition was confirmed by RT-PCR and western blot on hTERT mRNA and protein levels, respectively, and by measuring the activity level of telomerase using the TRAP assay. The effect of the hTERT siRNA on the tumorigenicity of the breast cancer cells was also studied <it>in vivo </it>by injection of the siRNA-transfected breast cancer cells into nude mice.</p> <p>The effects on cell viability, apoptosis and senescence of cells treated with hTERT siRNA, doxorubicin, and the combined treatment of doxorubicin and hTERT siRNA, were examined <it>in vitro </it>by MTT assay, FACS and SA-β-galactosidase staining.</p> <p>Results</p> <p>The hTERT siRNA effectively knocked down the mRNA and protein levels of hTERT, and reduced the telomerase activity to 30% of the untreated control. <it>In vivo</it>, the tumors induced by the hTERT siRNA-transfected cells were of reduced sizes, indicating that the hTERT siRNA also reduced the tumorigenic potential of the breast cancer cells. The siRNA treatment reduced cell viability by 50% in breast cancer cells within two days after transfection, while 0.5 μM doxorubicin treatment had a comparable effect but with a slower kinetics. The combination of hTERT siRNA and 0.5 μM doxorubicin killed twice as many cancer cells, showing a cumulative effect of the two treatments.</p> <p>Conclusion</p> <p>The study demonstrated the potential of telomerase inhibition as an effective treatment for breast cancer. When used in conjunction to doxorubicin, it could potentiate the cytotoxic effect of the drug to breast cancer cells.</p

Development of Cervical Massage Instrument imitating Manipulation

In order to meet the action effect of pushing, kneading, squeezing, pressing and rolling of nerve root type cervical spondylosis, a new type of cervical massage chair imitating manipulation treatment is developed, which adopts the structural scheme of the combination of massage handwheel and eccentric wheel. Based on NX software, the structure of each part of the cervical massage chair is designed, the virtual prototype is designed, and the finite element analysis of the transmission spindle is carried out. The results show that the structure design is reasonable, the simulation action meets the contra direction synchronous 8-shaped curve track designed by massage handwheel, and the assembly structure is reasonable without interference. Using 3D printing technology, a prototype model was made, which laid a foundation for the follow-up biomechanical analysis and clinical application

Development of Cervical Massage Instrument imitating Manipulation

In order to meet the action effect of pushing, kneading, squeezing, pressing and rolling of nerve root type cervical spondylosis, a new type of cervical massage chair imitating manipulation treatment is developed, which adopts the structural scheme of the combination of massage handwheel and eccentric wheel. Based on NX software, the structure of each part of the cervical massage chair is designed, the virtual prototype is designed, and the finite element analysis of the transmission spindle is carried out. The results show that the structure design is reasonable, the simulation action meets the contra direction synchronous 8-shaped curve track designed by massage handwheel, and the assembly structure is reasonable without interference. Using 3D printing technology, a prototype model was made, which laid a foundation for the follow-up biomechanical analysis and clinical application.</jats:p

Influences of advanced glycosylation end products on the inner blood–retinal barrier in a co-culture cell model in vitro

Advanced glycosylation end products (AGEs) are harmful factors that can damage the inner blood–retinal barrier (iBRB). Rat retinal microvascular endothelial cells (RMECs) were isolated and cultured, and identified by anti-CD31 and von Willebrand factor polyclonal antibodies. Similarly, rat retinal Müller glial cells (RMGCs) were identified by H&E staining and with antibodies of glial fibrillary acidic protein and glutamine synthetase. The transepithelial electrical resistance (TEER) value was measured with a Millicell electrical resistance system to observe the leakage of the barrier. Transwell cell plates for co-culturing RMECs with RMGCs were used to construct an iBRB model, which was then tested with the addition of AGEs at final concentrations of 50 and 100 mg/L for 24, 48, and 72 h. AGEs in the in vitro iBRB model constructed by RMEC and RMGC co-culture led to the imbalance of the vascular endothelial growth factor (VEGF) and pigment epithelial derivative factor (PEDF), and the permeability of the RMEC layer increased because the TEER decreased in a dose- and time-dependent manner. AGEs increased VEGF but lowered PEDF in a dose- and time-dependent manner. The intervention with AGEs led to the change of the transendothelial resistance of the RMEC layer likely caused by the increased ratio of VEGF/PEDF

Influences of advanced glycosylation end products on the inner blood–retinal barrier in a co-culture cell model in vitro

AbstractAdvanced glycosylation end products (AGEs) are harmful factors that can damage the inner blood–retinal barrier (iBRB). Rat retinal microvascular endothelial cells (RMECs) were isolated and cultured, and identified by anti-CD31 and von Willebrand factor polyclonal antibodies. Similarly, rat retinal Müller glial cells (RMGCs) were identified by H&amp;E staining and with antibodies of glial fibrillary acidic protein and glutamine synthetase. The transepithelial electrical resistance (TEER) value was measured with a Millicell electrical resistance system to observe the leakage of the barrier. Transwell cell plates for co-culturing RMECs with RMGCs were used to construct an iBRB model, which was then tested with the addition of AGEs at final concentrations of 50 and 100 mg/L for 24, 48, and 72 h. AGEs in the in vitro iBRB model constructed by RMEC and RMGC co-culture led to the imbalance of the vascular endothelial growth factor (VEGF) and pigment epithelial derivative factor (PEDF), and the permeability of the RMEC layer increased because the TEER decreased in a dose- and time-dependent manner. AGEs increased VEGF but lowered PEDF in a dose- and time-dependent manner. The intervention with AGEs led to the change of the transendothelial resistance of the RMEC layer likely caused by the increased ratio of VEGF/PEDF.</jats:p

GSE-YOLO: A Lightweight and High-Precision Model for Identifying the Ripeness of Pitaya (Dragon Fruit) Based on the YOLOv8n Improvement

Pitaya fruit is a significant agricultural commodity in southern China. The traditional method of determining the ripeness of pitaya by humans is inefficient, it is therefore of the utmost importance to utilize precision agriculture and smart farming technologies in order to accurately identify the ripeness of pitaya fruit. In order to achieve rapid recognition of pitaya targets in natural environments, we focus on pitaya maturity as the research object. During the growth process, pitaya undergoes changes in its shape and color, with each stage exhibiting significant characteristics. Therefore, we divided the pitaya into four stages according to different maturity levels, namely Bud, Immature, Semi-mature and Mature, and we have designed a lightweight detection and classification network for recognizing the maturity of pitaya fruit based on the YOLOv8n algorithm, namely GSE-YOLO (GhostConv SPPELAN-EMA-YOLO). The specific methods include replacing the convolutional layer of the backbone network in the YOLOv8n model, incorporating attention mechanisms, modifying the loss function, and implementing data augmentation. Our improved YOLOv8n model achieved a detection and recognition accuracy of 85.2%, a recall rate of 87.3%, an F1 score of 86.23, and an mAP50 of 90.9%, addressing the issue of false or missed detection of pitaya ripeness in intricate environments. The experimental results demonstrate that our enhanced YOLOv8n model has attained a commendable level of accuracy in discerning pitaya ripeness, which has a positive impact on the advancement of precision agriculture and smart farming technologies

Influences of advanced glycosylation end products on the inner blood-retinal barrier in a co-cultural cell model in vitro

Abstract Background: Advanced glycosylation end products (AGEs) are harmful factors that can damage the inner blood-retinal barrier (iBRB). However, their effects on iBRB co-culture models in vitro have not been reported. This study is to understand the interactive effects of different concentrations of AGEs at different time points on rat retinal microvascular endothelial cells (RMEC) and rat retinal Müller glial cell (RMGC) co-culture models. Methods: RMEC of Sprague-Dawley rat was isolated and cultured, identified by anti-CD31 flow cytometry and immunocytometry with von Willebrand factor polyclonal antibody. Similarly, RMGC of Sprague-Dawley rat was identified by H&amp;E staining, and immunohistochemical method with antibodies of Glial fibrillary acidic protein (GFAP) and glutamine synthetase (GS). The transepithelial electrical resistance (TEER) value was measured with the Millicell electrical resistance system to observe the leakage of the barrier. The Transwell cell for co-cultured RMEC with RMGC were used to construct an iBRB model and tested with the addition of AGEs at final concentrations of 50 mg/L and 100 mg/L, respectively, for 24 hours, 48 hours, and 72 hours.Results: AGEs in vitro iBRB model constructed by RMEC and RMGC co-culture led to the imbalance of VEGF and PEDF, and the permeability of the RMEC layer increased because TEER decreased in a dose- and time-dependent manner. In the AGEs intervention the vascular endothelial growth factor (VEGF) was increased, while pigment epithelial derivative factor (PEDF) decreased, respectively, in a dose- and time-dependent manner by enzyme-linked immunosorbent assay.Conclusions: The intervention with AGEs led to change of the RMEC layer transendothelial resistance and ratio of VEGF/PEDF. The iBRB in vitro model is a good tool to study the pathogenesis of retinal vascular diseases such as diabetic retinopathy and to evaluate the candidate drugs on the diseases.</jats:p

Bartter Syndrome Type 3: Phenotype-Genotype Correlation and Favorable Response to Ibuprofen

Objective: To investigate the phenotype-genotype correlation in different genetic kinds of Bartter syndrome type 3 in children.Methods: Clinical and genetic data of 2 patients with different mutations in Bartter syndrome type 3 was analyzed while the prognosis was compared after a 6-year follow-up or 2-year follow-up, respectively.Results: Bartter syndrome is a kind of autosomal recessive inherited renal disorder. The manifestation and prognosis of Bartter syndrome change with mutation types, and severe mutation were often accompanied with unfavorable prognosis. Comprehensive therapy with ibuprofen, antisterone, captopril, and potassium have remarkable effect, while ibuprofen may improve growth retardation partly.Conclusion: Bartter syndrome should be considered when children have unreasonable continuous electrolyte disturbance, metabolic alkalosis and growth retardation.As a genetic disease, its clinical features depend on the mutation type. It can be ameliorated by electrolyte supplementation, prostaglandin synthetase inhibitors, angiotensin-converting enzyme inhibitors and potassium-sparing diuretic. Considering the following electrolyte disturbances, infections, growth retardation, kidney failure and even death, Bartter syndrome need lifelong treatment, early diagnosis and treatment is the most important